<DOC>
	<DOCNO>NCT02462525</DOCNO>
	<brief_summary>This Phase 1/1b , open-label , dose-escalation study design evaluate safety , pharmacokinetics , determine recommend Phase 2 dose ABBV-838 subject relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Dose-Escalation Study ABBV-838 , Antibody Drug Conjugate , Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Eastern Cooperative Oncology Group Performance Status 0 2 Not eligible stem cell/bone marrow transplant refuse stem cell/bone marrow transplant relapse autologous allogeneic stem cell/bone marrow transplant Eligible agree BM aspirate prior treatment start Measurable disease M component serum ( ≥ 0.5 g/dL ) and/or urine ( ≥ 0.2 g excrete 24 hour collection sample ) Must receive least 3 prior line therapy include proteasome inhibitor immunomodulatory agent double refractory PI immunomodulatory agent demonstrate disease progression ( DP ) within 60 day completion last therapy ; participant previously treat alkylating agent , addition IMiD proteasome inhibitor , allow enroll trial Participants must adequate liver , kidney , bone morrow function Participants history chronic heart failure must cardiac ECHO indicate leave ventricular ejection fraction ( LVEF ) ≥ 45 % within 21 day prior first dose study drug Participants combination therapy arm must eligible receive pomalidomide/dexamethasone , bortezomib/dexamethasone lenalidomide/dexamethasone approve agent per current prescribe information MM . Participants receive combination therapy Pomalidomide/Dexamethasone must receive least two prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression within 60 day completion last therapy Received anticancer therapy include chemotherapy , immunotherapy , radiation , biologic , investigational therapy herbal therapy within period 21 day prior first dose ABBV838 , unresolved toxicity ≥ grade 2 Concurrent metastatic solid tumor NonMeasurable M Protein ( serum urine ) measurable sFLC ( &lt; 100 mg/mL ) Major surgery within 21 day prior first dose ABBV838 Clinically significant uncontrolled condition ( ) include limited following : Grade ≥ 3 peripheral neuropathy grade 2 peripheral neuropathy pain Uncontrolled hypercalcemia Active uncontrolled infection Symptomatic congestive heart failure Unstable angina pectoris cardiac arrhythmia Psychiatric illness/social situation would limit compliance study Major immunologic reaction IgG contain agent auristatin base agent Participants take strong CYP3A4 inhibitor Positive HIV ( Human Immunodeficiency Virus ) active hepatitis B and/or C Corneal pathology would limit evaluation loss visual acuity associate corneal deposit . Prior exposure pomalidomide subject enrol pomalidomide/dexamethasone combination arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapse multiple myeloma</keyword>
	<keyword>antibody drug conjugate</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>